Dozens of prescription medications can trigger a positive antinuclear antibody (ANA) test, sometimes without causing any symptoms at all. The best-known culprits are procainamide and hydralazine, but the list extends to anticonvulsants, biologic therapies, certain antibiotics, and antithyroid drugs, among others. A positive ANA from a medication does not automatically mean you have lupus or any other autoimmune disease, and the picture usually clears up once the offending drug is stopped. Still, understanding which drugs are involved and what the test result actually means can save you from unnecessary worry or, in rarer cases, alert you to a real problem developing.
The Classic Offenders
Procainamide and hydralazine have the longest and strongest track record of causing drug-induced ANA positivity. Procainamide, a heart rhythm medication, is so reliably linked to ANA development that the majority of people taking it long-term will eventually test positive. Hydralazine, a blood pressure drug, follows closely behind. Beyond these two, chlorpromazine, isoniazid, methyldopa, penicillamine, quinidine, and sulfasalazine are all recognized triggers, along with whole drug classes like anticonvulsants, beta-blockers, and sulfonamides.1SpringerLink (Drug Safety). Drug-induced lupus
What sets procainamide apart is both the rate at which it induces ANA and the specific type of antibody it produces. Patients on procainamide tend to develop strong antibodies against a particular histone protein complex called H2A-H2B. These antibodies appear well before any clinical symptoms show up and ramp up dramatically if a full-blown lupus-like episode develops.2The American Journal of Medicine. Serologic changes during induction of lupus-like disease by procainamide Hydralazine also produces anti-histone antibodies, but they tend to be weaker and qualitatively different from those caused by procainamide.3Clinical Immunology and Immunopathology. Reactivity of anti-histone antibodies induced by procainamide and hydralazine Neither drug typically triggers the kinds of antibodies seen in spontaneous lupus, such as anti-double-stranded DNA or anti-Sm antibodies.4PubMed. IgG antibodies to the histone complex H2A-H2B characterize procainamide-induced lupus
Anticonvulsants and Seizure Medications
Drugs used to control seizures are another well-established group of ANA inducers. Phenytoin, carbamazepine, and ethosuximide have all been linked to the development of antinuclear antibodies, and the phenomenon appears across multiple anticonvulsant types rather than being limited to a single chemical structure. In one study of 170 patients on long-term anticonvulsant therapy, significantly more had ANA compared to healthy controls, with antibodies directed mainly against specific nuclear protein components.5PubMed Central. Antinuclear antibodies in patients on anticonvulsant therapy
The same study found an interesting wrinkle: anticonvulsant-associated antibodies targeted different nuclear components than those induced by isoniazid, another known ANA trigger. Patients on isoniazid had antibodies mainly to whole nuclei and nucleoprotein, while the anticonvulsant group showed antibodies directed primarily against soluble nucleoprotein. This suggests that different drug classes may push the immune system in different directions, even though the end result on a standard ANA screening test looks the same.
In children, the picture is similar. A study of 60 children on anti-epileptic medications found that about 12% tested ANA-positive.6Acta Medica Iranica. The Prevalence of Serum Anti Nuclear Antibodies in Children Treated With Anti-Epileptics In a broader review of drug-induced lupus in childhood, ethosuximide was the single most commonly implicated drug, and ANA was positive in over 90% of those pediatric cases.7PubMed Central. Drug-induced lupus erythematosus in childhood: Case-based review
Biologic Therapies
Some of the most widely prescribed newer medications, particularly the TNF-alpha inhibitors used for rheumatoid arthritis, psoriasis, and inflammatory bowel disease, are potent inducers of ANA. Infliximab is the best studied. In one cohort of rheumatoid arthritis and spondyloarthropathy patients, ANA positivity jumped from about 40% to over 80% after infliximab treatment, and patients who had been entirely negative for anti-double-stranded DNA antibodies before treatment began testing positive.8PubMed. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy Another study of rheumatoid arthritis patients on infliximab found that ANA positivity at a meaningful titer climbed from 25% to 40% during treatment, with anti-double-stranded DNA antibodies rising from 3% to 26%.9PubMed Central. Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis
Inflammatory bowel disease patients on anti-TNF therapy show similar trends. In one study, roughly 44% of anti-TNF-treated patients had elevated ANA titers, and about 16% had elevated double-stranded DNA antibody levels.10PubMed. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease The reassuring part is that actual lupus-like symptoms remain uncommon in these patients. Most develop antibodies without ever feeling sick, which puts clinicians in the awkward position of seeing alarming lab values in patients who are clinically doing fine.
Immune checkpoint inhibitors, the cancer immunotherapy drugs that have transformed oncology in recent years, are another story. These drugs work by releasing the brakes on the immune system, so it is not surprising that autoimmune side effects sometimes follow. Among patients who developed liver inflammation from checkpoint inhibitors, about 18% tested ANA-positive, and among those with bile duct inflammation, the figure was closer to 42%.11PubMed Central. Autoantibodies in patients with immune-related adverse events from checkpoint inhibitors Unlike TNF inhibitors, checkpoint inhibitor-related autoimmunity tends to come with real symptoms, so a new positive ANA in a patient receiving cancer immunotherapy carries more clinical weight.
Minocycline and Antibiotics
Minocycline, the tetracycline antibiotic commonly prescribed for acne, occupies a special place in drug-induced autoimmunity. It tends to affect a younger population than most other drug-induced lupus culprits because acne treatment peaks in the teenage years and twenties. Dozens of cases of minocycline-induced lupus have been reported, along with cases of autoimmune hepatitis, and the two conditions sometimes occur simultaneously in the same patient.12PubMed. Coexistent minocycline-induced systemic lupus erythematosus and autoimmune hepatitis All reported cases involved positive ANA, but minocycline-induced lupus breaks from the usual pattern in that anti-histone antibodies are often absent, making it harder to distinguish from idiopathic lupus through antibody testing alone.
Minocycline also induces other autoantibodies. A cross-sectional study found that 7% of minocycline-exposed patients tested positive for antineutrophil cytoplasmic antibodies (ANCA), compared to none in the unexposed group.13PubMed. Is minocycline therapy in acne associated with antineutrophil cytoplasmic antibody positivity? A cross-sectional study The good news is that minocycline-induced autoimmune problems typically resolve after the drug is stopped, with symptoms clearing and lab values normalizing.14PubMed Central. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome
Antithyroid Medications
Propylthiouracil (PTU) and methimazole, the mainstay drugs for treating an overactive thyroid, can both induce autoantibodies. PTU has the stronger association. In a study comparing patients on these two drugs, both groups showed changes in antibody profiles, but PTU-treated patients were more likely to develop ANCA alongside ANA and anti-histone antibodies.15PubMed Central. Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs A separate study looking at both drugs found that the autoantibodies produced were likely a broad, nonspecific immune activation rather than a targeted autoimmune attack, though the clinical significance of this distinction is still debated.16PubMed. Anti-nuclear antibody, anti-DNA, and aCL in Graves’ disease patients treated with propyluracil or methimazole
The tricky part with antithyroid drugs is that Graves’ disease itself is autoimmune, so patients are already on an immune background that might predispose them to developing additional autoantibodies. Sorting out what is from the disease and what is from the medication requires looking at the timing: new antibodies appearing months into treatment point more strongly toward a drug effect.
How Drug-Induced ANA Differs From Lupus ANA
One of the most practical things to know is that drug-induced ANA usually looks different under the microscope and in follow-up testing than the ANA you see in idiopathic (spontaneous) lupus. The biggest clue is the type of nuclear target the antibodies recognize. In drug-induced lupus, the antibodies are overwhelmingly directed at histones, the spool-like proteins that DNA wraps around. In spontaneous lupus, the antibody population is much more diverse and includes antibodies against native DNA, histones, and various nonhistone nuclear proteins.17JCI Insight. Antibodies to Histones in Drug-Induced and Idiopathic Lupus Erythematosus
That said, anti-histone antibodies are not unique to drug-induced lupus. They also appear in a portion of spontaneous lupus patients. The pattern of which specific histones are targeted can vary and is not reliably drug-specific, meaning you cannot always tell which medication caused the problem based on the antibody profile alone.18Annals of the Rheumatic Diseases. Antibodies to the five histones and poly(adenosine diphosphate-ribose) in drug induced lupus: implications for pathogenesis Minocycline-induced lupus, as mentioned earlier, is an exception that frequently lacks anti-histone antibodies altogether, which can make diagnosis particularly confusing.
For clinicians trying to sort this out, the most helpful approach is usually a combination of timing (did the symptoms start after the drug was introduced?), antibody pattern (are anti-histone antibodies present while anti-double-stranded DNA is absent?), and clinical response (do things improve when the drug is stopped?). No single lab test settles the question on its own.
Why Some People Are More Susceptible
Not everyone on a given medication develops ANA, which raises the question of what makes certain people vulnerable. The answer involves both genetics and drug metabolism. A key factor is how quickly your body processes certain drugs through an enzyme pathway called acetylation. People who are “slow acetylators” break down drugs like procainamide, hydralazine, and sulfasalazine more slowly, leaving the drug and its metabolites circulating longer. This prolonged exposure appears to increase the odds of an immune reaction.
In a study of sulfasalazine-induced lupus, every single patient was found to be a slow acetylator. The same patients also carried certain immune system gene variants that are associated with spontaneous lupus, suggesting that drug-induced lupus tends to find people who are already genetically primed for autoimmunity.19British Journal of Rheumatology. Predisposing factors in sulphasalazine-induced systemic lupus erythematosus The practical takeaway is that drug-induced lupus is not purely bad luck: some people carry a biological predisposition that a medication simply activates.
As for the mechanism by which drugs trigger autoantibodies in the first place, the current thinking focuses on the innate immune system. Traditional drug-induced lupus agents appear to boost neutrophil responses, including the formation of neutrophil extracellular traps (NETs), which are web-like structures that neutrophils release when activated. These traps expose nuclear contents that normally stay hidden from the immune system, potentially prompting the body to produce antibodies against its own nuclear material.20PubMed. Drug-induced lupus: Traditional and new concepts
What Happens When You Stop the Drug
The hallmark of drug-induced ANA and drug-induced lupus is that it improves after the offending medication is withdrawn. Symptoms like joint pain, rashes, and fever typically resolve within days to weeks. But the antibodies themselves can be stubbornly persistent. In Crohn’s disease patients who developed ANA on anti-TNF therapy, only about one in five became seronegative after stopping infliximab, and the median time to seroconversion was about 12 months. In many patients, ANA persisted for at least a year after the last infusion.21PubMed. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn’s disease
This lag can cause real anxiety. You stop the drug, you feel better, but your blood work still shows a positive ANA for months. In most cases, this is simply the immune system taking its time to wind down. But there is a more unsettling possibility: in a small number of patients, a bout of drug-induced lupus appears to unmask a previously silent autoimmune condition. A case report in a patient who had drug-induced lupus found that atypical lab results continued long after the drug was removed, raising the question of whether the medication had awakened a dormant autoimmune process rather than creating one from scratch.22PubMed Central. Drug-Induced Lupus, a One-time Hit or a Harbinger of Future Autoimmunity This is not the norm, but it is a reason why follow-up monitoring after drug-induced lupus makes sense.
Positive ANA Without Any Drug Involvement
It is worth stepping back and acknowledging that a positive ANA test, by itself, is extremely common and frequently meaningless. In the general U.S. population, about 14% of people ages 12 and older test positive for ANA, with the rate higher in women (roughly 18%) than in men (about 10%) and increasing with age.23PubMed Central. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States Even among people with no known disease, ANA positivity at moderate titers is not unusual. In one study of healthy individuals, about 5% were ANA-positive at the 1:160 dilution that many labs use as their reporting threshold.24PubMed. Range of antinuclear antibodies in “healthy” individuals
This background noise matters because it sets the stage for misinterpretation. If you are taking one of the medications discussed above and your ANA comes back positive, it might be the medication, it might be your baseline, or it might be something else entirely. The ANA test is a screening tool, not a diagnosis. ANA positivity is found in healthy people, in people with non-rheumatic conditions, and across a range of medications, making the clinical context far more important than the test result itself.25PubMed Central. Antinuclear antibodies in healthy people and non-rheumatic diseases – diagnostic and clinical implications
Less Common and Emerging Triggers
The list of ANA-inducing medications continues to grow. Sulfasalazine, used for inflammatory bowel disease and rheumatoid arthritis, is an established trigger. Penicillamine, once used more often for rheumatoid arthritis and Wilson’s disease, is another older drug with a known association. Among newer agents, checkpoint inhibitors are a growing concern as their use expands across oncology. Even herbal supplements have been implicated in isolated case reports: one described a young woman who developed a full lupus-like syndrome with positive ANA after taking an herbal product, with rapid resolution after stopping it.26PubMed Central. Drug reaction with herbal supplement: a possible case of drug induced lupus erythematosus
The herbal supplement angle is particularly tricky because these products are often unregulated and may contain compounds that are not listed on the label. If you develop unexplained joint pain, rashes, or a positive ANA while taking supplements, it is worth bringing the full list of everything you are consuming to your doctor, not just your prescriptions.
As biologics and targeted therapies continue to proliferate, clinicians will likely be seeing more drug-induced ANA rather than less. The underlying principle remains the same: a positive ANA in the setting of a new medication deserves investigation, but it does not by itself mean you have lupus. The pattern of antibodies, the timing relative to the drug, the presence or absence of symptoms, and what happens when the drug is withdrawn all carry more diagnostic weight than the ANA number on its own.